Israeli - Kiingereza - Ministry of Health

astrazeneca (israel) ltd - selumetinib as hyd-sulfate - hard capsule - selumetinib as hyd-sulfate 10 mg - selumetinib - koselugo is indicated for the treatment of pediatric patients 2 years of age and older withneurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn).

Israeli - Kiingereza - Ministry of Health

astrazeneca (israel) ltd - selumetinib as hyd-sulfate - hard capsule - selumetinib as hyd-sulfate 25 mg - selumetinib - koselugo is indicated for the treatment of pediatric patients 2 years of age and older withneurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn).

Yordani - Kiingereza - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية أداتكو - adatco drug store - timolol 0.5 %, dorzolamide 2 % - 0.5%, 2%

Yordani - Kiingereza - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - imatinib 100 mg - 100 mg

Yordani - Kiingereza - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - imatinib 400 mg - 400 mg

Yordani - Kiingereza - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية أبوشيخة - abu sheikha drug store - fenofibrate 200 mg - 200 mg

Yordani - Kiingereza - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية ابن رشد - ibn rushd drug store - tamsulosin hcl 0.4 mg - 0.4 mg

Israeli - Kiingereza - Ministry of Health

abic marketing ltd, israel - teriparatide as acetate - solution for injection - teriparatide as acetate 250 mcg/ml - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture:teriparatide teva is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, teriparatide teva increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture :teriparatide teva is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture:teriparatide teva is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy

Israeli - Kiingereza - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - gastro resistant capsules - duloxetine as hydrochloride 30 mg - duloxetine - duloxetine sandoz is indicated for - the treatment of major depressive episodes.- the management of neuropathic pain associated with diabetic peripheral neuropathy.- the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia.- the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low back pain (clbp) and chronic pain due to osteoarthritis.

Israeli - Kiingereza - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - gastro resistant capsules - duloxetine as hydrochloride 60 mg - duloxetine - duloxetine sandoz is indicated for - the treatment of major depressive episodes.- the management of neuropathic pain associated with diabetic peripheral neuropathy.- the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia.- the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low back pain (clbp) and chronic pain due to osteoarthritis.